Members
Lars Bendtsen, Stine Maarbjerg, Henrik Winther Schytz and Jacob Worm.
Background
Trigeminal neuralgia is an extremely painful disease, which may be difficult to treat. Management consists of prophylactic pharmacotherapy and surgery in selected cases. There is a huge lack of high-quality research in this field and essential aspects such as epidemiology, pathophysiology, diagnosis, and optimal treatment are far from understood.
Current projects
Evaluation of long-term efficacy and side effects of neurosurgical- and medical treatments. Two randomized clinical trials investigating new promising treatment options; one investigating basimglurant, a negative allosteric modulator of the metabotropic glutamate receptor 5, and another investigating injection therapy with onabotulinumtoxinA, both as preventive treatments. The role of neuroinflammatory biomarkers in trigeminal neuralgia pathophysiology and as predictors of treatment response. Trigeminal neuralgia epidemiology investigating temporally associated diseases and disease progression to discover important comorbidities and possible risk factors.
Collaboration
- Emil A. Smilkov, Department of Diagnostic Radiology, Copenhagen University Hospital - Rigshospitalet, Glostrup, Denmark.
- Per Rochat, Department of Neurosurgery, Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark.
- Jacob Springborg, Department of Neurosurgery, Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark.
- Søren Brunak, NNF Center for Protein Research, University of Copenhagen, Copenhagen, Denmark.
- Thomas Folkmann Hansen, Department of Neurology, Danish Headache Center, NeuroGenomic Group, Copenhagen University Hospital - Rigshospitalet, Glostrup, Denmark.
- Noema Pharma AG, Basel, Switzerland.
Updated: 28-06-2024